1-(3-CHLORO-4-METHYLPHENYL)-3-[3-(2,6-DIOXO-PIPERIDIN-3-YL)-2-METHYL-4-OXO-3,4-DIHYDRO-QUINAZOLIN-6-YLMETHYL]-UREA | 1135008-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(3-CHLORO-4-METHYLPHENYL)-3-[3-(2,6-DIOXO-PIPERIDIN-3-YL)-2-METHYL-4-OXO-3,4-DIHYDRO-QUINAZOLIN-6-YLMETHYL]-UREA
• 英文别名: 1-(3-Chloro-4-methyl-phenyl)-3-[3-(2,6-dioxo-piperidin-3-yl)-2-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl]-urea；1-(3-chloro-4-methylphenyl)-3-[[3-(2,6-dioxopiperidin-3-yl)-2-methyl-4-oxoquinazolin-6-yl]methyl]urea
• CAS: 1135008-60-4
• 化学式: C₂₃H₂₂ClN₅O₄
• 分子量: 467.912
• InChiKey: HWMOUZJFQVXMBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(6-aminomethyl-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione hydrogenchloride 、 3-氯-4-甲基苯基异氰酸酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以70%的产率得到1-(3-CHLORO-4-METHYLPHENYL)-3-[3-(2,6-DIOXO-PIPERIDIN-3-YL)-2-METHYL-4-OXO-3,4-DIHYDRO-QUINAZOLIN-6-YLMETHYL]-UREA
  参考文献：
  名称：

  6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same

  摘要：

  提供了喹唑啉酮化合物，以及其药用盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。

  公开号：

  US20090093504A1

文献信息

• 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：Muller George W.

  公开号：US20130289274A1

  公开（公告）日：2013-10-31

  Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了喹唑酮类化合物及其药学上可接受的盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和制药组合物。
• 7-substituted quinazolinone compounds and compositions comprising the same
  申请人：Muller George W.

  公开号：US08492395B2

  公开（公告）日：2013-07-23

  Provided are quinazolinone compounds of formula (I), and pharmaceutically acceptable salts and stereoisomers thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了公式（I）的喹唑啉酮化合物及其药学上可接受的盐和立体异构体。公开了这些化合物的使用方法和药物组成物。
• 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
  申请人：Celgene Corporation

  公开号：US09096573B2

  公开（公告）日：2015-08-04

  Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof: wherein R7, R8, and R9 are as defined herein. Methods of use, and pharmaceutical compositions of these compounds are also disclosed herein.

  提供了喹唑啉酮化合物及其药学上可接受的盐、溶剂合物、笼合物、立体异构体和前药：其中R7、R8和R9的定义如本文所述。本文还披露了这些化合物的使用方法和制备药物组合物的方法。
• METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES
  申请人：Celgene Corporation

  公开号：EP3925609A1

  公开（公告）日：2021-12-22

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of pomalidomide with an anti-CSl antibody.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括服用泊马度胺和抗-CSl抗体。
• Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
  申请人：Celgene Corporation

  公开号：US10034872B2

  公开（公告）日：2018-07-31

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括在接受了自体干细胞移植的患者中使用免疫调节化合物，如来那度胺或泊马度胺与抗CS1抗体，如艾洛妥珠单抗。